What is the appropriate management of a Strattera (atomoxetine) overdose?

Management of Strattera (Atomoxetine) Overdose

Strattera overdose should be managed primarily with supportive care, including airway protection, seizure control with benzodiazepines, and cardiovascular monitoring, as there is no specific antidote and dialysis is ineffective due to high protein binding. 1

Immediate Assessment and Stabilization

Airway and Breathing

• Establish airway patency immediately and provide respiratory support as needed
• Intubation may be required if mental status is significantly depressed or seizures occur
• Standard BLS/ALS protocols take priority over any specific interventions 2

Contact Poison Control

Call 1-800-222-1222 (US) immediately for expert toxicology guidance - regional poison centers have board-certified toxicologists available 24/7 for case-specific management recommendations 2

Expected Clinical Presentation

Common Symptoms (Mild to Moderate)

The FDA label indicates most overdose events are mild to moderate, with the following symptoms 1:

• Gastrointestinal: Nausea, vomiting (most common)
• Neurological: Somnolence, dizziness, tremor, hyperactivity, agitation
• Sympathomimetic signs: Tachycardia, hypertension, mydriasis, dry mouth

Serious Complications (Less Common but Critical)

• Seizures - reported in multiple overdose cases 1, 3, 4
• QT prolongation and cardiac conduction abnormalities 1
• Mental status changes: Disorientation, hallucinations 1
• Cardiogenic shock - rare but life-threatening, may require VA-ECMO in extreme cases 5

Dose-Response Relationship

Research shows variable toxicity, but important thresholds include 6, 4:

• Doses >100 mg commonly produce tachycardia
• Doses >200 mg associated with moderate effects requiring intervention
• Hypertension reported at doses ≥480 mg
• No fatalities reported from isolated atomoxetine overdose up to 1400 mg 1

Specific Management Interventions

Gastrointestinal Decontamination

• Activated charcoal if patient presents within 1-2 hours of ingestion and can protect airway 4
• Consider gastric lavage only for massive, recent ingestions in intubated patients
• In the case report of severe cardiogenic shock, endoscopic medication removal was performed 5

Seizure Management

Benzodiazepines are first-line for seizure control 7:

• Lorazepam 2-4 mg IV (adults) or 0.05-0.1 mg/kg (pediatric)
• Diazepam 5-10 mg IV as alternative
• If refractory to benzodiazepines, consider propofol or dexmedetomidine 7

Cardiovascular Management

Monitor ECG continuously for QT prolongation and arrhythmias 1, 3:

• Obtain baseline ECG immediately
• Repeat ECG at 2-4 hour intervals until normalized
• Echocardiography if signs of cardiac dysfunction (hypotension, chest pain) 5
• Treat hypertension cautiously - usually self-limited and resolves with sedation
• For severe tachycardia unresponsive to benzodiazepines, consider short-acting beta-blockers

Agitation and Behavioral Disturbances

Benzodiazepines are first-line for agitation 7, 6:

• Escalate sedation as needed
• Second-line options if benzodiazepines fail: antipsychotics (ziprasidone, haloperidol) or dexmedetomidine 7

Advanced Interventions for Severe Cases

In the rare event of refractory cardiogenic shock 5:

• VA-ECMO may be lifesaving
• Intravenous lipid emulsion (ILE) was used successfully in one case report, though evidence is limited
• High-dose vasopressor/inotropic support

What NOT to Do

Ineffective Interventions

• Dialysis is NOT useful - atomoxetine is highly protein-bound (>98%) 1
• Forced diuresis has no role
• Flumazenil is contraindicated (atomoxetine is not a benzodiazepine) 2

Monitoring and Disposition

Observation Period

• Minimum 6-8 hours observation for all intentional overdoses
• Symptoms may be delayed up to 3 hours post-ingestion 6
• Most symptoms resolve within 24-30 hours 6, 4

Laboratory Monitoring

• Baseline and serial ECGs until QRS/QTc normalize
• Electrolytes (particularly if vomiting)
• Liver function tests if prolonged symptoms (atomoxetine can cause hepatotoxicity, though not typically in acute overdose)
• Serum atomoxetine levels are NOT clinically useful for acute management 1

Admission Criteria

Admit to monitored setting if:

• Seizures occurred
• Persistent tachycardia (HR >130 bpm) or hypertension
• QTc >500 ms or QRS widening
• Altered mental status
• Ingestion >500 mg in children or >1000 mg in adults
• Any cardiovascular instability

ICU admission if:

• Recurrent seizures
• Hemodynamic instability requiring vasopressors
• Cardiac arrhythmias beyond sinus tachycardia
• Severe mental status depression requiring intubation

Key Clinical Pitfalls

1. Don't assume benign course - while most overdoses are mild, seizures and cardiac toxicity can occur unpredictably
2. Delayed symptom onset - patients may appear well initially but deteriorate hours later 6
3. Mixed ingestions are common - maintain high suspicion for co-ingestants, particularly in intentional overdoses 1
4. Sympathomimetic toxicity mimics other conditions - consider atomoxetine in differential for unexplained tachycardia/agitation in ADHD patients

Pediatric Considerations

Children represent the majority of exposures 4:

• Lower threshold for admission (any symptomatic child)
• Tachycardia is the earliest and most common sign 6
• Mean heart rate in symptomatic children: 131 ± 14 bpm 4
• Activated charcoal appropriate for home management of small accidental ingestions if asymptomatic 4